Literature DB >> 6177408

Treatment of advanced malignant melanoma with vinblastine, bleomycin, and cisplatin.

E Bajetta, R Rovej, R Buzzoni, M Vaglini, G Bonadonna.   

Abstract

Thirty-two consecutive patients with metastatic malignant melanoma were treated with vinblastine, bleomycin, and cisplatin (VBD) chemotherapy. There were 29 evaluable patients; complete remission was observed in three and partial remission in five. No patient with visceral metastasis showed objective response. The 10-month survival rate of responders was significantly higher than that of nonresponders (57.1% vs 18.2%, P = 0.01); however, present results do not confirm that VBD is superior to other drug combinations for malignant melanoma.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6177408

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  3 in total

1.  Vinblastin-carboplatin for metastatic cutaneous melanoma as first-line chemotherapy and in dacarbazine failures: a single-center study.

Authors:  S Jelić; N Babović; L Stamatović; M Kreacić; S Matković; I Popov
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

2.  Alteration and activation of sequence-specific cleavage of DNA by bleomycin in the presence of the antitumor drug cis-diamminedichloroplatinum(II).

Authors:  P K Mascharak; Y Sugiura; J Kuwahara; T Suzuki; S J Lippard
Journal:  Proc Natl Acad Sci U S A       Date:  1983-11       Impact factor: 11.205

3.  Formation of a DNA monofunctional cis-platinum adduct cross-linking the intercalating drug N-methyl-2,7-diazapyrenium.

Authors:  J M Malinge; M Sip; A J Blacker; J M Lehn; M Leng
Journal:  Nucleic Acids Res       Date:  1990-07-11       Impact factor: 16.971

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.